Patient-Generated Health Data Collection During Chemoradiotherapy for Lung Cancer

Launched by THE NEW YORK PROTON CENTER · Mar 25, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how collecting health data from patients can help understand their experiences during treatment for lung cancer. Participants will use devices like an Apple Watch and a home pulse oximeter to track their health while they receive proton beam radiotherapy, a type of targeted radiation treatment. The study lasts from the time you join until two weeks after your treatment ends, and it aims to gather information on how patients feel and manage their health during this period. Participants will also fill out a short satisfaction survey at the end of the study.

To be eligible for this trial, you should be at least 18 years old and plan to undergo a specific type of radiation treatment for lung cancer, either non-small cell or small cell lung cancer. You can still join if you are receiving chemotherapy at the same time. It's important that you can complete surveys in English or Spanish and agree to use the devices provided by the study. However, if you are pregnant, trying to become pregnant, or currently being treated for another type of cancer, you may not be able to participate. This trial is currently recruiting participants, and all involved will need to sign consent forms to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Plan for fractionated (≥15 treatments) proton beam thoracic radiotherapy with curative intent for lung cancer
• • Non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) histology is permitted.
• • Concurrent chemotherapy is permitted but not required..
• • Previous thoracic radiotherapy is allowed.
• • Ability to complete study surveys in English or Spanish
• • Age \>/= 18
• • Concurrent enrollment on other trials is permitted
• • Patients who already use wearable devices and/or smartphones that monitor physical activity are eligible for this trial, provided they agree to utilize the devices provided by the study team during the study period
• • All patients must sign study-specific informed consent prior to study entry
• Exclusion Criteria:
• • Ongoing treatment for another cancer that is expected to affect the toxicity profile of thoracic radiotherapy
• • Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic